Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

illion and $37.4 million for the corresponding periods in 2006. The 2007 increase primarily resulted from higher sales and marketing expenses associated with the expansion of ISTA's sales force in early 2007. Stock-based compensation expenses included in SG&A for the fourth quarter and for the year ended December 31, 2007 were $0.8 million and $2.5 million, respectively.

The net loss for the fourth quarter and year ended December 31, 2007, was $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share), respectively, compared with a net loss of $6.4 million (or $0.25 per share) and $38.4 million (or $1.48 per share) for the same periods in 2006. At December 31, 2007, ISTA had cash and short-term investments of $46.1 million.

2007 Corporate Highlights

-- Increased net revenue by 56% and 78% as compared to the fourth quarter

of 2006, and year ended December 31, 2006, respectively

-- Filed an NDA with the FDA for Xibrom QD (once-daily) in December of

2007 after announcing, earlier in the year, positive Phase III results

for Xibrom QD as a treatment for inflammation, pain, and photophobia

following cataract surgery

-- Announced statistically significant Phase II/III study results for

Bepreve in treating ocular itching and clinical improvement in redness

and initiated both the Bepreve ocular safety study and the second

Phase III study

-- Announced positive results from the ecabet sodium Phase IIb study for

the treatment of dry eye syndrome

-- Successfully completed $36.7 million financing through the private

placement of 5.25 million shares of common stock with institutional

accredited investors at a purchase price of $7.00 per share

-- Expanded pipeline in allergy treatments by licensing exclusive North

American rights to nasal dosage forms of bepotastine, an

investigation
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Investor-Edge has initiated coverage ... GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ), ... research report on Genetic Technologies can be accessed ... 2015, the NASDAQ Composite ended at 4,941.42, down ...
(Date:5/1/2015)... DALLAS , May 1, 2015 ... report "Antibody Production Market by Product (Equipment, Consumables), by ... (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis ... the report studies the global Antibody Production Market ... This market is expected to reach $2.572 Billion ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... 30, 2015   Tamir Biotechnology , a leading ... on its Ebola antiviral therapy program. ... is currently being evaluated and considered by a number ... Ebola. During the first quarter of 2015, the company ... Accelerate The Evaluation of Potential Treatments and Vaccines For ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Ohio, June 22, 2011 With the intent to ... disease in Akron, the Austen BioInnovation Institute in Akron ... the conference "Healthier by Design: Creating Accountable Care Communities" ... regional health and wellness thought-leaders, the strategic discussion is ...
... Colorado Institute for Drug, Device and Diagnostic Development ... the Colorado life science ecosystem through company creation ... Veterinary Emerging Technologies Development Corporation (VetDC) to receive ... commercializes technologies to address serious unmet medical needs ...
... 2011 VENENUM Biodesign, a drug discovery company that ... to identify potential therapeutic agents against its novel disease-based ... opened its new medicinal chemistry space at 8 Black ... facility comprises over 11,000 square feet of state-of-the-art research ...
Cached Biology Technology:Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 2Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 3Colorado Institute for Drug, Device and Diagnostic Development Awards Funding to Fort Collins-based VetDC 2VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Department of Energy,s (DOE),s National Renewable Energy Laboratory ... Capital (SAPC) working group with a mission to ... cash flows in the marketplace. SAPC,s primary ... agreements, leases, and other documents relevant to residential ...
... , First economic models showing impact of post-weaning multi-systemic ... to 84 per pig lost, depending on severity of PMWS, ... Stark new figures show that a common pig virus, ... implications for individual farmers and the pig industry as a whole, ...
... can pass down from one generation to the next ... of genetics. Scientists have shown that an enzyme in ... changes in gene activity an example of epigenetics. ... directly affect DNA sequences. Though some evidence has suggested that ...
Cached Biology News:NREL assembles industry working group to advance solar securitization 2Pig wasting syndrome costing farmers millions 2Researchers find novel way plants pass traits to next generation 2Researchers find novel way plants pass traits to next generation 3Researchers find novel way plants pass traits to next generation 4